Thierry Lafont

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

Journal: Chemotherapy

Published: July 30, 2024

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury.

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury.

Journal: Metabolites

Published: August 13, 2022

Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.

Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.

Journal: Therapeutic drug monitoring

Published: May 26, 2020

Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.

Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.

Journal: Pharmaceutical research

Published: April 09, 2020

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Journal: British journal of clinical pharmacology

Published: November 06, 2018

Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.

Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: May 09, 2018

Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

Journal: Cancer chemotherapy and pharmacology

Published: February 19, 2018

Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.

Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.

Journal: Journal of pharmaceutical and biomedical analysis

Published: November 22, 2017

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Journal: Cancer chemotherapy and pharmacology

Published: November 05, 2015

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Journal: Investigational new drugs

Published: September 17, 2015

Pharmacokinetics of pazopanib administered in combination with bevacizumab.

Pharmacokinetics of pazopanib administered in combination with bevacizumab.

Journal: Cancer chemotherapy and pharmacology

Published: February 18, 2014

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.

Journal: British journal of clinical pharmacology

Published: November 16, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026